BI Asset Management Fondsmaeglerselskab A S Sells 1,550 Shares of McKesson Corporation $MCK

BI Asset Management Fondsmaeglerselskab A S lessened its stake in shares of McKesson Corporation (NYSE:MCK) by 5.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 27,376 shares of the company’s stock after selling 1,550 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in McKesson were worth $21,149,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Norges Bank acquired a new position in McKesson in the 2nd quarter worth about $1,346,661,000. Alliancebernstein L.P. grew its holdings in shares of McKesson by 150.4% during the second quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock worth $1,661,956,000 after purchasing an additional 1,362,386 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of McKesson by 56.4% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock valued at $906,109,000 after buying an additional 446,060 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in McKesson by 45.6% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 833,780 shares of the company’s stock valued at $610,977,000 after buying an additional 261,296 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its position in McKesson by 68.0% during the 2nd quarter. Acadian Asset Management LLC now owns 636,596 shares of the company’s stock worth $466,441,000 after buying an additional 257,670 shares during the period. 85.07% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Thomas L. Rodgers sold 276 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the sale, the executive vice president directly owned 2,268 shares in the company, valued at $1,851,096.24. This trade represents a 10.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $861.63, for a total value of $283,476.27. Following the transaction, the chief accounting officer directly owned 328 shares in the company, valued at approximately $282,614.64. This trade represents a 50.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.08% of the company’s stock.

Key Stories Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Q3 results beat expectations — McKesson reported adjusted EPS above consensus and revenue roughly in line, driven by volume growth across distribution. Read More.
• Positive Sentiment: Raised FY‑2026 profit guidance — management nudged full‑year adjusted EPS to a range of 38.800–39.200, citing strength in oncology and specialty drug distribution. That modest beat versus consensus supports the growth story. Read More.
• Neutral Sentiment: Analyst sentiment remains largely positive — multiple firms maintain buy/overweight ratings and price targets above current levels (median targets near $860+), so market expectations stay elevated. Read More.
• Neutral Sentiment: Revenue outcome mixed vs. Street — total revenue was essentially in line with estimates, limiting the upside surprise. Read More.
• Negative Sentiment: Operating cash flow weakness — the quarter showed a sharp drop in cash from operations versus last year, raising concerns about working‑capital swings and free‑cash‑flow reliability. Read More.
• Negative Sentiment: Balance sheet and returns red flags — investors pointed to a negative reported return on equity and a rise in total liabilities, which can temper valuation multiples despite strong top‑line. Read More.
• Negative Sentiment: Insider selling and strategic exits — recent insider sales and McKesson’s full exit from the European market add near‑term uncertainty and may prompt profit‑taking. Read More. Read More.

McKesson Price Performance

Shares of NYSE:MCK opened at $819.58 on Thursday. McKesson Corporation has a 1 year low of $570.51 and a 1 year high of $895.58. The business’s 50-day moving average is $825.54 and its 200-day moving average is $776.66. The company has a market capitalization of $101.16 billion, a price-to-earnings ratio of 25.51, a P/E/G ratio of 1.40 and a beta of 0.40.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The business had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a negative return on equity of 248.14% and a net margin of 1.04%.The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the previous year, the company posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Analysts anticipate that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 annualized dividend and a yield of 0.4%. McKesson’s dividend payout ratio is currently 10.21%.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on MCK shares. Wells Fargo & Company upped their price target on shares of McKesson from $816.00 to $914.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Robert W. Baird set a $968.00 price objective on McKesson in a report on Wednesday, January 14th. Jefferies Financial Group lifted their target price on McKesson from $820.00 to $900.00 and gave the stock a “buy” rating in a report on Monday, October 13th. Morgan Stanley reissued an “overweight” rating and issued a $966.00 price target on shares of McKesson in a research note on Thursday, January 29th. Finally, Barclays began coverage on McKesson in a research note on Monday, December 8th. They issued an “overweight” rating and a $960.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, McKesson currently has a consensus rating of “Moderate Buy” and an average target price of $899.36.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.